U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235618) titled 'A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer' on Nov. 14.
Brief Summary: This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival [PFS]), and explore the correlation between peripheral blood mononuclear cell (PBMC) acetylation levels and treatment response to determine the baseline acetylation threshold .
Study Start Date: Jan. 05, 2026
Study Type: INTERVENTIONAL
Condition:
Locally Advanced o...